Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities.

Abstract

The goal of phase I cancer trials is to determine the highest dose of a treatment regimen with an acceptable toxicity rate. Traditional designs for phase I trials, such as the Continual Reassessment Method (CRM) and the 3 + 3 design, require each patient or a cohort of patients to be fully evaluated for the dose-limiting toxicity (DLT) before new patients… (More)
DOI: 10.1002/sim.4255

Topics

9 Figures and Tables

Cite this paper

@article{Polley2011PracticalMT, title={Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities.}, author={Mei-Yin C. Polley}, journal={Statistics in medicine}, year={2011}, volume={30 17}, pages={2130-43} }